EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial

Nick van Es, Luuk J J Scheres, Kristen M Sanfilippo, Harry Büller, Marc Carrier, Marcello Di Nisio, Michael Grosso, Renato D Lopes, William F McIntyre, Bjorn Redfors, Annelise Segers, Peter Verhamme und 3 weitere

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2025.11.024 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Nick van Es und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Neth…. Hauptthemen laut MEDLINE: Thiazoles, Pyridines, Venous Thromboembolism, Dalteparin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Hokusai Venous Thromboembolism (VTE) Cancer trial demonstrated that edoxaban was noninferior to dalteparin for the treatment of cancer-associated venous VTE. OBJECTIVES: We reanalyzed the trial using the win ratio, an approach that evaluates a composite of outcomes in a hierarchical order. METHODS: Forty-nine thrombosis experts ranked 10 outcomes in order of clinical importance from all-cause death (most important) to clinically relevant nonmajor bleeding (least important). We performed unmatched pairwise comparisons between participants on edoxaban and those on dalteparin at 6- and 12-month follow-up. Within each pair, edoxaban was assigned a win, loss, or tie according to the hierarchy of outcomes. We calculated the win ratio (total wins divided by total losses among edoxaban patients), with more wins than losses indicating the benefit of edoxaban, and the win difference (total wins minus total losses). RESULTS: Among 273 528 pairs (522 × 524 participants), edoxaban was associated with a win in 34.9%, a loss in 38.5%, and a tie in 26.6%. The win ratio was 0.91 (95% CI, 0.76-1.08), with a win difference of -3.55% (95% CI, -9.9% to 2.9%) at 12 months. The win ratio remained unchanged at 6 months (0.91; 95% CI, 0.75-1.11). The findings were consistent with a hierarchy of only death, recurrent VTE, and major bleeding (win ratio, 0.92; 95% CI, 0.76-1.11), or when replacing all-cause death with VTE-related death or fatal bleeding (win ratio, 0.83; 95% CI, 0.65-1.06). CONCLUSION: We observed no significant difference between edoxaban and dalteparin for the treatment of cancer-associated VTE when using the win ratio approach with a hierarchy of 10 prioritized outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazolesPyridinesVenous ThromboembolismDalteparinNeoplasmsFactor Xa InhibitorsAnticoagulantsHumansHemorrhageTreatment OutcomeMaleFemaleTime FactorsMiddle AgedAgedJapanRisk FactorsRisk Assessment

Stichwörter der Autor:innen

anticoagulantscancerrandomized controlled trials as topicvenous thromboembolism

Substanzen

edoxabanThiazolesPyridinesDalteparinFactor Xa InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: n.vanes@amsterdamumc.nl.
  • Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medicine, Washington University School of Medicine in St. Louis, Saint Louis, Missouri, USA; Department of Medicine, St. Louis Veterans Administration Medical Center, St. Louis, Missouri, USA.
  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Medicine and Ageing Sciences, "G. D'Annunzio" University, Chieti, Italy.

Zitieren

APA

van Es, N., Scheres, L. J. J., Sanfilippo, K. M., Büller, H., Carrier, M., Di Nisio, M., Grosso, M., Lopes, R. D., McIntyre, W. F., Redfors, B., Segers, A., Verhamme, P., Weitz, J. I., Bossuyt, P. M., & Siegal, D. M. (2026). The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.11.024

Vancouver

van Es N, Scheres LJJ, Sanfilippo KM, Büller H, Carrier M, Di Nisio M, et al. The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2025.11.024

BibTeX
@article{vanEs2026,
  author = {van Es, Nick and Scheres, Luuk J J and Sanfilippo, Kristen M and Büller, Harry and Carrier, Marc and Di Nisio, Marcello and Grosso, Michael and Lopes, Renato D and McIntyre, William F and Redfors, Bjorn and Segers, Annelise and Verhamme, Peter and Weitz, Jeffrey I and Bossuyt, Patrick M and Siegal, Deborah M},
  title = {The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2025.11.024}
}
Kostenlos starten →